VIRMEDIUM SIGNALOPERATIONAL10-K

VIR has successfully advanced its hepatitis delta ECLIPSE program from planned initiation to active enrollment with two trials completing enrollment ahead of expectations, while simultaneously expanding its oncology pipeline to three active Phase 1 TCE programs.

The progression from "scheduled to commence" to active trials with accelerated enrollment suggests strong operational execution and potentially favorable regulatory positioning for the hepatitis delta program. However, the removal of HBV program details and shift toward partnership-seeking language indicates potential strategic refocusing or resource constraints in certain therapeutic areas.

Comparing 2026-02-23 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

VIR's financial position shows mixed signals with current assets declining significantly by 50.7% to $514.1M, yet stockholders' equity increased substantially by 45.1% to $2.1B, suggesting potential equity raises or favorable revaluations. Operating performance improved modestly with operating losses narrowing from -$587.2M to -$479.3M and reduced SG&A expenses of 22.6%, indicating better cost management despite continued high cash burn rates typical for a clinical-stage biotech company.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
-50.7%
$1.0B$514.1M

Current assets declined 50.7% — monitor working capital adequacy and short-term liquidity.

Stockholders Equity
Balance Sheet
+45.1%
$1.4B$2.1B

Equity base grew 45.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Capital Expenditure
Cash Flow
-33.8%
$7.3M$4.8M

Capex reduced 33.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
-28.3%
$1.4B$1.0B

Total assets contracted 28.3% — asset sales, write-downs, or balance sheet optimization underway.

SG&A Expense
P&L
-22.6%
$119.0M$92.1M

SG&A reduced 22.6% — improved cost efficiency or headcount reduction improving operating margins.

Current Liabilities
Balance Sheet
-22.4%
$119.7M$92.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Income
P&L
+18.4%
-$587.2M-$479.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+16.1%
-$522.0M-$438.0M

Net income grew 16.1% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+12.2%
-$446.4M-$391.8M

Operating cash flow grew 12.2% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-02-23
PRIOR — 2025-02-27
ADDED
In hepatitis delta, we have initiated our registrational ECLIPSE clinical program evaluating the tobevibart and elebsiran combination in people living with chronic hepatitis delta (CHD).
The three randomized, controlled trials (ECLIPSE 1, 2, and 3) are ongoing, with ECLIPSE 1 and 3 completing enrollment ahead of the Company s expectations.
Topline results from ECLIPSE 1 are expected in the fourth quarter of 2026 with topline results from ECLIPSE 2 and 3 expected in the first quarter of 2027.
In oncology, we are advancing three Phase 1 clinical studies of dual-masked T-cell engagers (TCEs): VIR-5500 in patients with Prostate-Specific Membrane Antigen (PSMA)-expressing metastatic castration-resistant prostate cancer (mCRPC); VIR-5818 in patients with HER2-expressing tumors; and VIR-5525 in patients with EGFR-expressing tumors.
We are developing therapeutic candidates in HIV cure and multiple solid tumors.
+7 more — sign up free →
REMOVED
In hepatitis delta, our phase 3 ECLIPSE registrational program evaluating the combination of tobevibart and elebsiran is scheduled to commence in the first half of 2025.
In oncology, we are advancing phase 1 clinical studies for our dual-masked T-cell engagers (TCEs): VIR-5818 in patients with HER2-expressing tumors and VIR-5500 in patients with PSMA-expressing metastatic castration-resistant prostate cancer (mCRPC).
We are also advancing our third TCE program, VIR-5525, in patients with EGFR-expressing tumors, with phase 1 clinical studies are expected to begin in the first half of 2025.
We are also developing therapeutic candidates in hepatitis B virus (HBV), HIV cure, and other solid tumors, leveraging our expertise and platform strengths.
Advancement of our HBV program beyond the current MARCH study is contingent upon securing a worldwide (excluding People s Republic of China, Taiwan, Hong Kong and Macau, collectively the China Territory ) development and commercialization partner.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →